[1] |
Lee AS, de Lencastre H, Garau J, et al. Methicillin⁃resistant Staphylococcus aureus[J]. Nat Rev Dis Primers, 2018,4:18033. doi: 10.1038/nrdp.2018.33.
|
[2] |
Luepke KH, Suda KJ, Boucher H, et al. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications[J]. Pharmacotherapy, 2017,37(1):71⁃84. doi: 10.1002/phar.1868.
|
[3] |
Jamal M, Bukhari S, Andleeb S, et al. Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields[J]. J Basic Microbiol, 2019,59(2):123⁃133. doi: 10.1002/jobm.201800412.
|
[4] |
Chanishvili N. Phage therapy⁃⁃history from Twort and d′Herelle through Soviet experience to current approaches[J]. Adv Virus Res, 2012,83:3⁃40. doi: 10.1016/B978⁃0⁃12⁃394438⁃2.00001⁃3.
|
[5] |
Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy.Antimicrob Agents Chemother, 2001,45(3):649⁃659. doi: 10. 1128/AAC.45.3.649⁃659.2001.
|
[6] |
Almeida GM, Leppänen M, Maasilta IJ, et al. Bacteriophage imaging: past, present and future[J]. Res Microbiol, 2018,169(9):488⁃494. doi: 10.1016/j.resmic.2018.05.006.
|
[7] |
安瑞. 噬菌体治疗的前世、今生与未来——对话微生物学界噬菌体专家[J]. 科学通报, 2017,62(23):2577⁃2580.
|
[8] |
Nilsson AS. Phage therapy⁃⁃constraints and possibilities[J]. Ups J Med Sci, 2014,119(2):192⁃198. doi: 10.3109/03009734.2014. 902878.
|
[9] |
Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics[J]. Trends Biotechnol, 2010,28(12):591⁃595. doi: 10.1016/j.tibtech.2010.08. 001.
|
[10] |
Weber⁃Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute′s experience[J]. Arch Immunol Ther Exp (Warsz), 2000,48(6):547⁃551.
|
[11] |
Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double⁃blind phase 1/2 trial. Lancet Infect Dis, 2019,19(1):35⁃45. doi:10.1016/S1473⁃3099(18)30482⁃1.
|
[12] |
Morozova VV, Vlassov VV, Tikunova NV. Applications of bacteriophages in the treatment of localized infections in humans[J]. Front Microbiol, 2018,9:1696. doi: 10.3389/fmicb. 2018.01696.
|
[13] |
Markoishvili K, Tsitlanadze G, Katsarava R, et al. A novel sustained⁃release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds[J]. Int J Dermatol, 2002,41(7):453⁃458. doi:10.1046/j.1365⁃4362.2002.01451.x
|
[14] |
Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial[J]. J Wound Care, 2009,18(6):237⁃238,240⁃243. doi: 10.12968/jowc.2009.18.6.42801.
|
[15] |
Morozova VV, Kozlova YN, Ganichev DA, et al. Bacteriophage treatment of infected diabetic foot ulcers[J]. Methods Mol Biol, 2018,1693:151⁃158. doi: 10.1007/978⁃1⁃4939⁃7395⁃8_13.
|
[16] |
Fish R, Kutter E, Wheat G, et al. Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials[J]. Methods Mol Biol, 2018,1693:159⁃170. doi: 10.1007/978⁃1⁃4939⁃7395⁃8_14.
|
[17] |
Totté J, van Doorn MB, Pasmans S. Successful Treatment of Chronic Staphylococcus aureus⁃related dermatoses with the topical endolysin Staphefekt SA.100: a report of 3 cases[J]. Case Rep Dermatol, 2017,9(2):19⁃25. doi: 10.1159/000473872.
|
[18] |
van Bijnen EM, Paget WJ, den Heijer CD, et al. Primary care treatment guidelines for skin infections in Europe: congruence with antimicrobial resistance found in commensal Staphylococcus aureus in the community[J]. BMC Fam Pract, 2014,15:175. doi: 10.1186/s12875⁃014⁃0175⁃8.
|
[19] |
首例超级细菌感染患者经噬菌体治疗痊愈[EB/OL]. [2019⁃05⁃25]. http://www.sh.chinanews.com/yljk/2018⁃08⁃15/43418.shtml.
|
[20] |
Kuipers S, Ruth MM, Mientjes M, et al. A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient[J]. Antimicrob Agents Chemother, 2019,64(1):e01281⁃19. doi: 10. 1128/AAC. 01281⁃19.
|
[21] |
Rostkowska OM, Międzybrodzki R, Miszewska⁃Szyszkowska D, et al. Treatment of recurrent urinary tract infections in a 60⁃year⁃old kidney transplant recipient. The use of phage therapy[J]. Transpl Infect Dis, 2020:e13391. doi: 10.1111/tid.13391.
|
[22] |
Leitner L, Sybesma W, Chanishvili N, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo⁃controlled, double⁃blind clinical trial[J]. BMC Urol, 2017,17(1):90. doi: 10.1186/s12894⁃017⁃0283⁃6.
|
[23] |
Zalewska⁃Piątek B, Piątek R. Phage therapy as a novel strategy in the treatment of urinary tract infections caused by E. Coli[J]. Antibiotics (Basel), 2020,9(6):304. doi: 10.3390/antibiotics906 0304.
|
[24] |
Bhattarai SR, Yoo SY, Lee SW, et al. Engineered phage⁃based therapeutic materials inhibit Chlamydia trachomatis intracellular infection[J]. Biomaterials, 2012,33(20):5166⁃5174. doi: 10.1016/ j.biomaterials.2012.03.054.
|
[25] |
练婷婷, 魏世娟, 刘原君, 等. M13⁃IN5重组噬菌体的构建与鉴定及其对沙眼衣原体的作用研究[J]. 中华皮肤科杂志,2018,51(12):859⁃864. doi: 10.3760/cma.j.issn.0412⁃4030.2018. 12.002.
|